Effects of Weight Loss From Bariatric Surgery on Intraocular Pressure (IOP) (IOP)
The Effects of Weight Loss From Bariatric Surgery on Intraocular Pressure
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Contacts and Locations
Study Locations
-
-
Texas
-
Bellaire, Texas, United States, 77401
- Minimally Invasive Surgeons of Texas
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18
- Written informed consent obtained
- BMI > 40 kg/m2 without associated comorbidities or > 35 kg/m2 with associated comorbidities. In the normal indication for routine bariatric surgery, comorbidities include hypertension, type II diabetes, venous stasis, sleep apnea, polycystic ovary syndrome, pseudotumor cerebri, nonalcoholic steatohepatitis, gastroesophageal reflux disease, coronary artery disease, degenerative joint disease, cancer, and hypercholesterolemia.
Exclusion Criteria:
- Current use of systemic steroids
- Any systemic medication which is unstable and can affect IOP
- History or evidence of glaucoma
- Any ocular trauma or ocular surgery
- Outside normal range of corneal thickness (500-600 microns)
- Unable to follow-up for 3 years
- Participating in any investigational device or medication study within 30 days of baseline
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Study group-Bariatric procedure performed
|
|
Control group: No bariatric procedures
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Intraocular pressure
Time Frame: Data will be recorded the same day when a patient comes to the clinic.
|
Data will be recorded the same day when a patient comes to the clinic.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Robert Feldman, M.D., The University of Texas Health Science Center, Houston
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 08-0499
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.